Gordon, K.; Warren, R.; Gottlieb, A.; Blauvelt, A.; Tha├ži, D.; Poulin, Y.; Boehnlein, M.; Brock, F.; Arendt, C.; Reich, K. Durable Efficacy of Certolizumab Pegol Dosed at 400 Mg Every Two Weeks Over 128 Weeks in Patients With Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2, and CIMPACT). J of Skin 2020, 4, s81.